Lori J. Wirth, MD

Articles

Differentiated Thyroid Cancer: Unmet Needs and Future Directions

May 20th 2022

Experts highlight remaining unmet needs in the management of radioiodine-refractory differentiated thyroid cancer and share their hopes for the future.

Practical Advice for Community Endocrinologists and Oncologists Treating DTC

May 13th 2022

Before closing out their discussion on radioiodine-refractory DTC management, experts share practical advice for community physicians.

Patient Surveillance and Therapy Selection in RAIR DTC

May 13th 2022

Shared insight on active surveillance practices for patients with radioiodine-refractory DTC and how disease factors play into selection of therapy at time of recurrence.

Defining RAI-Refractory DTC and Selecting Patients for Disease Monitoring

May 6th 2022

Reflecting on a real-world patient scenario of DTC, experts consider how they identify radioiodine-refractory disease and when they would initiate systemic therapy.

Patient Profile 2: Diagnosing and Assessing DTC

May 6th 2022

Expert Lori Wirth, MD, highlights key points from a second real-world patient scenario of radioiodine-refractory differentiated thyroid cancer.

Treatment of DTC With Lenvatinib: Managing Adverse Events

April 29th 2022

Expert advice on addressing adverse events, particularly through dose holds or reduction, in patients on lenvatinib therapy for radioiodine-refractory DTC.

Optimizing the Use of Lenvatinib in DTC: Patient Selection and Dosing

April 29th 2022

Shared insight on selecting appropriate patients for lenvatinib therapy in differentiated thyroid cancer, as well as optimizing dosing strategies in the context of clinical trial data.

Role of Endocrinologists and Oncologists in the Management of DTC

April 22nd 2022

A brief discussion on where endocrinologists and oncologists respectively fit into the differentiated thyroid cancer treatment paradigm.

Factors in Selecting Treatment for DTC

April 22nd 2022

Reflecting on the first patient scenario of radioiodine-refractory DTC, experts share their considerations for optimally selecting and sequencing therapy in this setting.

Patient Profile 1: Lenvatinib in the Treatment of RAI-Refractory DTC

April 15th 2022

Perspectives on the use of lenvatinib therapy to manage a patient with radioiodine-refractory DTC, preceding broader considerations for sequencing kinase inhibitor therapy.

Patient Profile 1: Radioiodine-Refractory Differentiated Thyroid Cancer

April 15th 2022

Expert Marcia Brose, MD, details a clinical scenario wherein a patient is diagnosed with differentiated thyroid cancer and managed with surgical and radiotherapy.

Novel Treatment Advances in Differentiated Thyroid Cancer

February 3rd 2022

An overview of therapies in the pipeline for differentiated thyroid cancer and their potential effect on clinical decision-making.

Second-Line Treatment Approaches for DTC

February 3rd 2022

Naifa L. Busaidy, MD, FACP, FACE, recognizes the importance of reassessing patients prior to considering a second-line therapy for differentiated thyroid cancer.

BRAF Inhibitors and Immunotherapy for Differentiated Thyroid Cancer

February 3rd 2022

The role of BRAF inhibitors and checkpoint inhibitors in differentiated thyroid cancer, and potential considerations for using BRAF inhibition as redifferentiation therapy.

RET and NTRK Inhibitors for Differentiated Thyroid Cancer

January 28th 2022

The rationale for targeting actionable mutations in differentiated thyroid cancer with RET and NTRK inhibitors.

Systemic Therapy Algorithms in DTC

January 28th 2022

Considerations regarding approaches to sequencing therapies for differentiated thyroid cancer.

Targeted Treatments for Differentiated Thyroid Cancer

January 21st 2022

An overview of the types of targeted drug classes available to treat differentiated thyroid cancer at various clinical stages.

When to Initiate Therapy for Differentiated Thyroid Cancer

January 21st 2022

Maria E. Cabanillas, MD, describes what triggers her to initiate therapy for differentiated thyroid cancer and variables that impact treatment choice.

Dr. Wirth on the Utility of Tipifarnib in Head and Neck Cancer

January 4th 2022

Lori J. Wirth, MD, discusses the utility of tipifarnib in patients with head and neck cancer whose tumors harbor HRAS mutations.

Dr. Wirth on the LIBRETTO-531 Trial With Selpercatinib in RET+ Medullary Thyroid Cancer

November 5th 2021

Lori J. Wirth, MD, discusses the phase 3 LIBRETTO-531 trial of selpercatinib in patients with RET-mutant medullary thyroid cancer.